Dr. Sharma’s current endeavor is focused on addressing the critical need for effective therapies in CNS metastases of melanoma, an area in which modern systemic therapy has made minimal progress with patients continuing to show extremely poor outcomes in checkpoint refractory disease. Dr. Sharma has shown an aptitude for meticulous drug development and has rapidly developed important skills in the unique modeling of the metastatic tumor environment. Recently, Saurabh's application was accepted to the SITC Sparkathon-2023 in prestigious program for promising early investigators to develop high priority immunotherapy projects under direct mentorship of society leaders for development of brain nano targeted immunotherapy. Recently he has applied for the 2023 Society for Immunotherapy of Cancer (SITC) Bristol Myers Cancer Immunotherapy Translational Fellowship Award. Prior to joining the Prof. Amanda R. Kirane (Director of cutaneous melanoma surgery) at Surgery Department, Stanford School of Medicine, Stanford university, Dr. Sharma got the opportunity to work on novel immuno-nanoconjugates for brain cancer (Glioblastoma) as a Postdoctoral Chemist and Pharmacologist under the mentorship of Prof. Ali Khademhosseini (Biomaterial, Tissue Engineering Pioneer, EX-MIT and EX-UCLA Professor and Current CEO, Terasaki Institute) and Prof. Eggehard Holler (EX-Director of Nanomedicine, Cedar Sinai Medical Research Center, Los Angeles, California) at Terasaki Institute for Biomedical Innovation, Los Angeles, California, USA. He worked as an assistant Professor at Department of Pharmaceutical Sciences, School of Health Sciences, UPES Dehradun, India. He pursued his Ph.D (Doctoral Degree) from BITS-Pilani, Pilani Campus, Rajasthan, India. During the PhD research work, Dr. Sharma has designed & developed the novel drug delivery systems for the delivery of the genetic materials (e.g., miRNA, siRNA) and chemotherapeutic agents. The research has a significant contribution in the field of developing novel treatment strategies for cancer therapy. He has experienced significant success in his early career, prior to joining post-doctoral program, as evidenced by his guest Speaker in VIT, Parul University and International Virtual Conference on Recent Trends in Life Sciences. He received a Council of Scientific & Industrial Research (CSIR-SRF) Senior Research Fellowship Award and several presentation awards at various International conferences. Further in detail, Dr. Sharma has shown significant success and contribution in his field as evident by: Dr Sharma holds two granted patents one US patent, PCT and other Indian patent in the field of developing novel drug delivery systems. Dr. Sharma published more than 24 publications (Since 2018, Citations:218, h-Index:10, I10-Index:10) his work at Internationally reputed high-Impact factor journal which included: Advance Science, Small, Lab On a Chip, Acta Biomaterialia, Biomaterials Advances (Materials Science and Engineering: C), Nanomedicine: Nanotechnology, Biology and Medicine, Regenerative Biomaterials, Applied Surface Science, Molecular pharmaceutics, International Journal of Pharmaceutics etc several others.

Honors & Awards

  • SITC Sparkathon Class of 2023, The Society for Immunotherapy of Cancer (SITC) (Sept. 27-29, 2023)
  • Best New Technology Award at SITC-Sparkathon-2023, The Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting & Pre-Conference Programs (Nov. 1–5, 2023)
  • Society For Melanoma Research (SMR) Travel Award on Brain Targeted Nano-Immunotherapy, Society For Melanoma Research (SMR) (6-9 November 2023)
  • Expert Research Chapter talk on Nanomedicine Platform technology for Cancer treatments, Institute of Biomaterials, Tribocorrosion, Nano and Regenerative Medicine, VIT, Vellore, India (2023)

Stanford Advisors

Research Interests

  • Science Education

Current Research and Scholarly Interests

We develop strategies to transport immunotherapeutic molecules across the blood-brain barrier for imaging and treating brain metastatic cancer. Currently, under the mentorship of Dr. Amanda Kirane, I have continued my work in cancer-targeted nanotechnology for the treatment of melanoma brain metastases. Immunotherapy of small peptides, small molecules.

Lab Affiliations

All Publications

  • The Utilisation of Mushroom Leftovers, Oats, and Lactose-Free Milk Powder for the Development of Geriatric Formulation. Foods (Basel, Switzerland) Paul, S., Kaushik, R., Upadhyay, S., Akhtar, A., Chawla, P., Kumar, N., Sharma, S., Rani, P. 2024; 13 (11)


    This study aims to focus on developing a food supplement for the geriatric population using disposal mushrooms, oats, and lactose-free milk powder. Lactose intolerance is most common in older adults, raising the demand for lactose-free foods. One of the major global challenges currently faced by humankind is food waste (FW). Most of the food that is produced for human consumption has not been utilized completely (1/3rd-1/2 unutilized), resulting in agricultural food waste. Mushrooms are highly valuable in terms of their nutritional value and medicinal properties; however, a significant percentage of mushroom leftovers are produced during mushroom production that do not meet retailers' standards (deformation of caps/stalks) and are left unattended. Oats are rich in dietary fibre beta-glucan (55% water soluble; 45% water insoluble). Lactose-free milk powder, oats, and dried mushroom leftover powder were blended in different ratios. It was observed that increasing the amount of mushroom leftover powder increases the protein content while diluting calories. The product with 15% mushroom powder and 30% oat powder showed the highest sensory scores and the lowest microbial count. The GCMS and FTIR analyses confirmed the presence of ergosterol and other functional groups. The results of the XRD analysis showed that the product with 15% mushroom powder and 30% oat powder had a less crystalline structure than the product with 5% mushroom powder and 40% oat powder and the product with 10% mushroom powder and 35% oat powder, resulting in more solubility. The ICP-OES analysis showed significant concentrations of calcium, potassium, magnesium, sodium, and zinc. The coliform count was nil for the products, and the bacterial count was below the limited range (3 × 102 cfu/g). The product with 15% mushroom powder and 30% oat powder showed the best results, so this developed product is recommended for older adults.

    View details for DOI 10.3390/foods13111738

    View details for PubMedID 38890965

    View details for PubMedCentralID PMC11171652

  • Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple-Negative Breast Cancer ADVANCED THERAPEUTICS Sharma, S., Pradhan, R., Lee, D., Sharma, M., Nasab, S., Hejmady, S., Chander, S., Mohaghegh, N., Maity, S., Khan, S., Khademhosseini, A., Kirane, A. 2024
  • Phenylthiazolidin-4-one piperazine Conjugates: Design, Synthesis, anticancer and antimicrobial studies RESULTS IN CHEMISTRY Singh, D., Patel, R., Aggarwal, A., Das, A., Sharma, S., Behera, B., Panigrahy, R., Kirane, A. R., Kharkwal, H., Kumar, P., Bokolia, N., Sankaranarayanan, M., Chander, S. 2024; 7
  • Design, Synthesis, Anticancer and Antimicrobial Studies of 2-Phenylthiazolidin-4-one Glycinamide Conjugates CHEMISTRYSELECT Singh, D., Aggarwal, A., Patel, R., Das, A., Sharma, S., Behera, B., Panigrahy, R., Maity, S., Kirane, A. R., Kharkwal, H., Sankaranarayanan, M., Wadhwa, P., Khan, A., Alshehri, J. M., Chander, S. 2023; 8 (42)
  • Apatite-coated Ag/AgBr/TiO2 nanocomposites: Insights into the antimicrobial mechanism in the dark and under visible-light irradiation APPLIED SURFACE SCIENCE Mohaghegh, N., Endo-Kimura, M., Wang, K., Wei, Z., Najafabadi, A., Zehtabi, F., Kouchehbaghi, N., Sharma, S., Markowska-Szczupak, A., Kowalska, E. 2023; 617
  • Influence of Nanocarrier Type on the Drug Delivery Aspects of Docetaxel: Empirical Evidences JOURNAL OF PHARMACEUTICAL INNOVATION Alshahrani, S. M., Thotakura, N., Sharma, S., Quadir, S., Chaurawal, N., Sharma, S., Chitkara, D., Raza, K. 2023; 18 (2): 641-652
  • Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma Kirane, A., Lee, D., Ahmad, M., Sharma, S., Serasanambati, M., Lowe, M., Applebee, C., Safrygina, E., Swetter, S., Reddy, S., Warner, A., Funchain, P., Wang, J., Levy, R., Larijani, B., Maverakis, E. SPRINGER. 2024: S33-S34